• The Company’s R&D subsidiary, GeNeuro Innovation, in Lyon, France, was selected for its unique expertise in human endogenous retroviruses
• The HERVCOV project aims to develop precision medicine and therapeutic solutions through the diagnosis of patients affected by the expression of the envelope protein of the W family of human endogenous retroviruses (W-ENV)
• GeNeuro Innovation will contribute to the implementation of diagnostic and therapeutic tools on an industrial scale to treat the syndromes linked to W ENV identified by this multidisciplinary study of a large panel of molecular, biological and clinical parameters of patients
• Initially focused on COVID-19 and post-COVID syndromes, this study will also provide information on other diseases associated with W-ENV, with the aim of proposing new precision medicine solutions based on the analysis of biomarkers, symptoms and disease progression
• Subsidy of 6.8 M€ paid by the European Commission and which involves research centres, companies and associations from Croatia, Spain, France, Greece and Italy